New findings about alirocumab therapy from the common conference of the American College of Cardiology and the World Congress of Cardiology 2020

Czech version

Authors: Ivan Tkáč
Authors‘ workplace: Excelentný tím pre výskum aterosklerózy (EXTASY), IV. interná klinika UPJŠ LF a UN LP Košice
Published in: AtheroRev 2020; 5(2): 124-126
Category: Clinical Studies

Sources

Blom D, Harada-Shiba M, Rubba P et al. Alirocumab efficacy and safety in adults with homozygous familiar hypercholesterolemia (ODYSSEY HoFH). Presentation ACC 2020. Dostupné z WWW: <https://www.tctmd.com/slide/alirocumab-efficacy-and-safety-adults-homozygous-familial-hypercholesterolemia-odyssey-hofh>.
Schwartz GG, Steg PG, Szarek M et al. [ODYSSEY OUTCOMES Committees and Investigators]. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097–2107. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1801174>.
Sabatine MS, Giugliano RP, Leech AC et al. [FOURIER Steering Committee and Investigators]. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
Kastelein JJP, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J 2015; 36(43): 2996–3003. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv370>.
Gaudet D, López-Sendón JL, Averna M et al. Efficacy and safety of alirocumab in a real-life setting in patients with or without familial hypercholesterolemia: The ODYSSEY APPRISE Study. J Am Coll Cardiol 2020; 75(11 Suppl 1): 1958. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)32585–7>.
Daniels SR, Caprio S, Chaudhari U et al. The efficacy and safety of alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: ODYSSEY KIDS. J Am Coll Cardiol 2020; 75(11 Suppl 1): 1860. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)32487–6>.
Bittner V, McGinnis J, Schwartz GG et al. Alirocumab and cardiovascular outcomes in women after an acute coronary syndrome: An ODYSSEY OUTCOMES trial analysis. J Am Coll Cardiol 2020; 75(11 Suppl 1): 1854. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)32481–5>.
Szarek M, Valgimigli M, Zeiher A et al. Effect of alirocumab on first and total revascularizations in patients with recent acute coronary syndrome in the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2020; 75(11 Suppl 1): 157. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)30784–1>.
Hagstrom E, Steg PG, Szarek M et al. Apolipoprotein B, PCSK9 inhibition with alirocumab, and ischemic cardiovascular events after acute coronary syndrome: Insights from the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2020; 75(11): 75. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)30702–6>.
Landmesser U, McGinniss J, Steg PG et al. Achievement of new European dyslipidemia-guideline low-density lipoprotein cholesterol treatment goals after acute coronary syndrome: Insights from ODYSSEY OUTCOMES. J Am Coll Cardiol 2020; 75(11 Suppl 1): 1978. Dostupné z DOI: <http://dx.doi.org/10.1016/S0735–1097(20)32605-X>.